PET/CT-Guided Neoadjuvant Tislelizumab Plus Chemotherapy/Chemoradiotherapy for Resectable Esophageal Squamous Cell Carcinoma: RATIONALE-213 Final Analysis

Tislelizumab with chemotherapy/chemoradiotherapy as neoadjuvant treatment for resectable ESCC yielded promising pCR rates and favorable survival outcomes with a tolerable safety profile in both PET-/CT-guided responders and PET nonresponders.

Authors

Institutions

Publication Details

Journal
Clinical Cancer Research
Published
2026-03-02
DOI
https://doi.org/10.1158/1078-0432.ccr-25-2367
Primary Topic
Esophageal Cancer Research and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

PET/CT-Guided Neoadjuvant Tislelizumab Plus Chemotherapy/Chemoradiotherapy for Resectable Esophageal Squamous Cell Carcinoma: RATIONALE-213 Final Analysis

Yongde Liao, Yushang Yang, L. Chen, Xiaolong Yan et al.
Clinical Cancer Research
Esophageal Cancer Research and Treatment
article

PET/CT-Guided Neoadjuvant Tislelizumab Plus Chemotherapy/Chemoradiotherapy for Resectable Esophageal Squamous Cell Carcinoma: RATIONALE-213 Final Analysis

Yongde Liao, Yushang Yang, L. Chen, Xiaolong Yan, Junfeng Liu, Xinyu Mei, H J Jiang, Lei Liang, Yang Shi, Zhang Zhang, Mingqiang Kang, Lijie Tan
article en

Abstract

Tislelizumab with chemotherapy/chemoradiotherapy as neoadjuvant treatment for resectable ESCC yielded promising pCR rates and favorable survival outcomes with a tolerable safety profile in both PET-/CT-guided responders and PET nonresponders.

Clinical Cancer Research
Hebei Medical University (CN), University of Science and Technology of China (CN), Fujian Medical University (CN), Sichuan University (CN), Fudan University (CN), Tianjin Medical University Cancer Institute and Hospital (CN), West China Hospital of Sichuan University (CN), Fourth Hospital of Hebei Medical University (CN), Beijing Enterprises (China) (CN), Danone (China) (CN), Tang Du Hospital (CN), Huazhong University of Science and Technology Hospital (CN), Huazhong University of Science and Technology (CN), Air Force Medical University (CN)
Good health and well-being
Openalex Percentile: Top 37%
Esophageal Cancer Research and Treatment
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

PET/CT-Guided Neoadjuvant Tislelizumab Plus Chemotherapy/Chemoradiotherapy for Resectable Esophageal Squamous Cell Carcinoma: RATIONALE-213 Final Analysis — Yongde Liao, Yushang Yang, et al. · Clinical Cancer Research (2026) | TGRS Research Map | TGRS